The phosphatidylinositol 3-kinases (PI3Ks) regulate cell growth, proliferation and survival, and are frequently affected in human cancer. PI3K is composed of a catalytic subunit, p110, and a regulatory subunit, p85. The PI3K catalytic subunit p110d is encoded by PIK3CD and contains p85-and RAS-binding domains, and a kinase domain. Here we present an alternatively spliced PIK3CD transcript encoding a previously unknown protein, p37d, and demonstrate that this protein is expressed in human ovarian and colorectal tumors. p37d retains the p85-binding domain and a fraction of the RAS-binding domain, lacks the catalytic domain, and has a unique carboxyl-terminal region. In contrast to p110d, which stabilizes p85, p37d promoted p85 sequestering. Despite the truncated RAS-binding domain, p37d bound to RAS and we found a strong positive correlation between the protein levels of p37d and RAS. Overexpressing p37d, but not p110d, increased the proliferation and invasive properties of HEK-293 cells and mouse embryonic fibroblasts. Cells overexpressing p37d showed a quicker phosphorylation response of AKT and ERK1/2 following serum stimulation. Ubiquitous expression of human p37d in the fruit fly increased body size, DNA content and phosphorylated ERK1/2 levels. Thus, p37d appears to be a new tumor-specific isoform of p110d with growthpromoting properties.
Introduction
Phosphatidylinositol 3-kinases (PI3Ks) regulate cell growth, survival and oncogenic transformation (Engelman et al., 2006) . Members of this protein family are frequently affected in human cancer by mutation or differential expression (Zhao and Vogt, 2008) . The most extensively studied PI3K (Type IA) is a heterodimer composed of a p85 regulatory subunit and a p110 catalytic subunit. The p85 subunit protects p110 from degradation and inhibits its enzymatic activity in quiescent cells. However, when cells are stimulated by activation of receptors with intrinsic tyrosine kinase activity, p85 promotes the translocation of p110 to the plasma membrane, where PI3K substrates are found (Skolnik et al., 1991; Yu et al., 1998) . Any of the three different Type IA isoforms of p110, called p110a, p110b and p110d, can sustain cell proliferation and survival (Foukas et al., 2010) . The physiological role of the a-, b-and d-isoforms is not fully understood, but their differential tissue distribution and the distinct phenotypes produced by their genetic ablation in mice indicate that each isoform has a distinct function (Vanhaesebroeck et al., 2005) . Moreover, the b-and d-isoforms of p110 can induce oncogenic transformation when expressed in chicken embryo fibroblasts (Kang et al., 2006) , and the activity of the p110a and p110b requires association with GTPbound RAS (Rameh et al., 1995) . The regulatory PI3K subunit, p85, can act in an oncogenic manner as shown in ovarian and colon tumors (Philp et al., 2001) , but p85 also has tumor suppressive properties (Taniguchi et al., 2010) . The main focus in cancer research has been on the a-and b-isoforms of p110, and it is primarily the catalytic activity of these enzymes that has been studied (Vogt et al., 2009) . However, it has been shown that the p110b isoform has distinct non-catalytic functions in cell proliferation and trafficking (Jia et al., 2008) .
The p110d isoform of PI3K is predominantly expressed in cells of the immune system and contributes to cellular and humoral immunity (Patton et al., 2007) as well as proliferation and prevention of apoptosis of B lymphocytes (Bilancio et al., 2006) . In acute myeloid leukemia p110d is essential for PI3K activation and cell proliferation (Sujobert et al., 2005) . The gene encoding p110d (PIK3CD) is also expressed in neuroblastoma , where it is occasionally mutated (Caren et al., 2007) , and in breast cancer cells, where it stimulates chemotaxis in response to the epidermal growth factor (Sawyer et al., 2003) . In contrast to the a-and b-isoforms of p110, the oncogenic activity of p110d is resistant to inhibitors of the MAP kinase pathway and does not require binding to RAS (Denley et al., 2008) .
In this study we identified a previously unknown protein in the PI3K pathway, p37d, which is encoded by an alternative splice product of PIK3CD, and document that this protein is overexpressed in human tumors and that it has growth-promoting properties.
Results

p37d is a new isoform of PI3K p110d
When cloning full length PIK3CD-mRNA from human peripheral blood leukocytes using standard cloning procedures, we identified an alternatively spliced transcript of PIK3CD (p110d-mRNA) that we designated as PIK3CD_v2 (p37d-mRNA), GenBank: JN190435, which encoded a 37 kDa protein that we called p37d. Expression of p37d-mRNA results from the use of an alternative splice site in intron 5 of PIK3CD, which produces a 163-bp insertion in the mature mRNA. The insertion results in a frame shift and premature termination of the protein (Figure 1a) . The translation product, p37d, is a 302 amino-acid protein containing the p85 binding domain and a truncated RAS-binding domain but lacks the catalytic domain. Moreover, the splicing results in translation of intron 5 sequences fused with out-of-frame sequences from exon 6 to produce an extra 102 amino-acid-long peptide sequence. This peptide does not correspond to known protein motifs (Figure 1b) . The sequence around the alternative splice site in intron 5 is conserved among several mammalian species (Figure 1c ). Predicted proteins resulting from alternative splicing using this splice site would generate proteins in a size range between 26 (mouse) and 37 (human) kDa (Figures 1a and b) , all encoding proteins with an intact p85-binding domain, a truncated RASbinding domain and lacking the catalytic domain ( Figure 1b ). As p110d, p37d is not ubiquitously expressed, however, detectable in some tissues. We detected the p37d protein in extracts of the human thymus, lung and spleen as judged by direct western blotting ( Figure 1d ) and the 26 kDa mouse protein in the spleen and lung samples as judged by western blotting after immunoprecipitation with a p85 antibody, the 26 kDa protein was not detectable in human cells (Figure 1e ).
High-level expression of p37d in human tumors
The levels of p37d protein were low in lysates of normal colon and ovarian biopsies as judged by western blotting using an antibody recognizing the N-terminus of p110d (Figure 2a ). p37d was elevated in lysates from colorectal tumors and very abundant in some ovarian tumors (Figure 2a) .
To assess baseline levels of p37d-mRNA expression, we screened RNA from 34 different tissues. p37d-mRNA was expressed at low levels in a majority of tissues, and similar to earlier studies (Vanhaesebroeck et al., 1997; Kok et al., 2009 ) full-length PIK3CD was detected in all tissues with the highest levels in lymphocytes (Supplementary Figure 1a ). To further analyze the expression of p37d-mRNA and p110d-mRNA, we screened eight human ovarian tumors of various stages by real-time PCR using a TaqMan Assays-by-Design system (Applied Biosystems, Foster City, CA, USA). The expression of p37d-mRNA was increased 3-450-fold in tumors compared with normal ovary (Figure 2b and Supplementary Figure 1b) . The expression of p110d-mRNA was consistently low (Figure 2b ).
We next screened 27 paired samples of colorectal tumors of stage II, III or IV and corresponding normal adjacent mucosa (10 cm from tumor). Overall, there was a 11-fold increase in p37d-mRNA expression in tumors compared with adjacent normal tissue (range, 1.4-100-fold, Po0.001). The expression of p37d-mRNA was significantly higher in stage II than in stage III and IV tumors ( Figure 2b and Supplementary Figure 1c) . Moreover, expression of p37d-mRNA was significantly higher in tumor-adjacent normal tissue compared with the healthy control colon (Figure 2b ). In order to investigate if the increased p37d-mRNA levels in tumors and tumor-adjacent normal tissue was due to increased The p110d isoform p37d is overexpressed in tumors S Fransson et al leukocyte infiltration we assessed a CD45-specific mRNA assay to the samples, a weak correlation was detected in the tumors, however, no correlation was seen in the normal tissues (Supplementary Figure 2) . These results suggest that p37d-mRNA expression may be an early event in tumorigenesis. The expression of fulllength p110d-mRNA was elevated in the colorectal tumors compared with the normal colon and tumoradjacent mucosa, however, the variance was great and the expression did not differ between tumor stages ( Figure 2b ). There was a correlation between p37d-mRNA levels and p110d-mRNA levels in the colorectal tumors and corresponding tumor-adjacent tissue (Supplementary Figure 3) .
p37d interacts with p85 and RAS To determine if p37d or p110d could stabilize p85, we transfected HEK-293 cells with vectors encoding p110d, p37d and p85. In these cells, expression of p110d lead to stabilization of p85 (Figure 3a) , however, the absolute levels of p37d and p85 were markedly reduced when p85 was co-transfected with p37d, compared with both cotransfection experiments with p85/p110d or with single transfections (Figure 3a) . The lack of p85 stabilizing upon expression of p37d could be because of lower amounts of p37d. To test this we used proteasome inhibition in the experiment. This caused elevated levels of p37d, however, still no stabilization of p85 was seen ( Figure 3b ). This experiment also indicated that overexpressed p37d, but not p110d, is sensitive to proteasomal degradation ( Figure 3b ). To determine if p37d could associate with p85 and RAS we performed co-immunoprecipitation experiments. The p37d protein bound to p85, as expected ( Figure 3c) . Surprisingly, despite the truncated RASbinding domain, we found association between p37d and H-RAS (Figure 3c ). The association between p37d and H-RAS was similar in starved (GDP-RAS) and in serum-stimulated (GTP-RAS) cells (Figure 3d ), suggesting that the RAS-binding is independent of RAS-GTP loading.
Ectopically expressed p85 localized in cytoplasmic aggregates (Figure 3e bottom), a pattern consistent with previous reports for endogenous p85 (Luo et al., 2005) . p37d aggregated in the cytoplasm together with p85 as judged by co-transfection of GFP-fused p85 and dsRED-fused p37d ( 
Overexpression of p37d enhances proliferation and invasive properties of cultured cells
To determine the impact of p37d expression on the proliferation and invasive properties of cultured cells, we generated mouse embryonic fibroblast (MEF) cells that stably overexpressed p37d and compared their growth rate with control mock-transfected clones (control). The p37d-expressing clones proliferated significantly faster than control (P ¼ 0.03, n ¼ 3, Figure 4a ). In addition, the p37d-expressing MEF clones exhibited increased invasive ability in a cell invasion assay compared with control (74 ± 13% invaded cells in p37d-expressing clones compared with 46±8% for the control clones, Po0.001; Figure 4b ). We further evaluated cell proliferation in human HEK-293 cells stably transfected with p37d or p110d and compared them with mock-transfected cells (control). Overexpression of p37d in HEK-293 cells increased proliferation (Po0.01, n ¼ 5, Figure 4c ) whereas overexpression of p110d had no effect ( Figure 4c ). As expected, suppression of p37d by small interfering RNA (siRNA) reduced proliferation of p37d overexpressing cells ( Figure 4d ). There was no colony-forming ability of p37d-expressing clones. Thus, expression of p37d in spontaneously immortalized MEFs increased proliferation and invasion but did not result in full oncogenic transformation.
The results in Figure 3a suggested that overexpression of p37d resulted in reduced levels of p85 (Figure 3a) . To determine if reduced levels of p85 per se affected cell proliferation we transfected control HEK-293-cells with scrambled or p85a-siRNA. This siRNA was The p110d isoform p37d is overexpressed in tumors S Fransson et al specific to p85a and did not reduce the levels of the shorter p55a/p50a isoforms, suggesting that the siRNA targeted only the 5 0 end of the PIK3R1 mRNA (Supplementary Figure 4) . Knockdown of p85a increased cell proliferation (Figure 4c , Supplementary  Figure 4) , suggesting that the ability of p37d to increase cell proliferation might be related to its ability to reduce levels of p85.
Downregulation of p37d decreases RAS protein levels and phosphorylated ERK1/2 As shown in Figures 3c and d, p37d co-immunoprecipitated with RAS, suggesting a possible association between p37d and RAS. Consistent with this idea, a linear correlation between the protein levels of p37d and RAS were observed in primary tissues (colorectal tumors and adjacent mucosa) (Figure 5a) , and between RAS and phospho-ERK1/2 in the same tissues (Figure 5a ). No correlation was observed for p110d and RAS and phospho-ERK1/2 (Supplementary Figure 5) .
If p37d has a direct or indirect stabilizing effect on RAS, then lowering the protein levels of p37d in p37d-expressing cells would also lower the RAS levels. For verification, we treated p37d-expressing HEK-293 cells with siRNA, to suppress p37d. This resulted in reduced RAS levels in cells treated with p37d-suppressing siRNA compared with control cells (treated with scrambled siRNA) (Figure 5b ). The high levels of RAS in cells overexpressing p37d correlated with high levels of phospho-ERK1/2; and both the levels of RAS and phospho-ERK1/2 were reduced after siRNA-treatment (Figure 5b ). These effects were not seen in siRNAtreated control-cells (Figure 5c ). Together, these data suggest that p37d could have stabilizing effect on RAS Quick pERK and pAKT response in p37d overexpressing cells To investigate if overexpression of p37d or p110d influences the response to growth stimuli, we serum starved HEK-293 cells stably overexpressing p37d or p110d, followed by serum stimulation. We detected both a quicker and a stronger response on the phosphorylation of both ERK and AKT S473 in p37d-expressing cells compared with control ( Figure 6a ). p110d-expressing cells showed a quicker response on phosphorylation of ERK (Figure 6a ). No change in the pAKT T308 levels could be detected (data not shown).
In long-term stimulation (10% serum), p37d cells showed higher basal levels of pAKT T308 (P ¼ 0.01) and slightly lower levels of pAKT S473 (Po0.01), compared with control cells (Figure 6b ). Higher basal level of pAKT T308 was also detected in p85a-siRNA treated cells (Supplementary Figure 4) . The pERK-levels were undetectable by western blot in all long-term-stimulated cells (data not shown).
To test if the cell proliferation advantage of p37d-expressing cells would be abrogated by inhibiting the PI3K or MAPK pathways, we cultured HEK-293 cells stably overexpressing p37d or p110d with the general PI3K -inhibitor, LY294002, or the MAPK-inhibitor, AZD6244. The inhibitors strongly affected the levels of phosphorylated AKT S473 and ERK (Figure 6c ). Although the PI3K inhibitor, LY294002, generally decreased cell proliferation, none of the inhibitors were able to abrogate the growth advantage of p37d overexpressing cells compared with control cells (Figure 6d) , indicating other or combinations of mechanisms to be involved.
Expression of p37d in Drosophila increases body size
To test the importance of p37d in vivo, we assessed the effect of human p37d expression in Drosophila melanogaster. Transgenic flies were generated to enable expression of human p37d, and the transgenes were expressed ubiquitously during development, using the UAS/Gal4 system with da-Gal4 as the driver. The adult flies were analyzed 2 days after emerging from the pupae. Expression of p37d caused a significant increase in total body weight of the flies by 7% compared with control flies (Figures 7a and b) . The larger body weights correlated with elevated DNA content (12%) of the flies (Figure 7b ). The p37d-expressing flies had 7% larger wings than control flies and the wing cell density was (Figures 7a and b) , indicating a larger total number of cells in the wings of the p37d-expressing flies. Excluding size, the flies expressing p37d looked phenotypically normal (Figure 7a ). Expression of human p37d also resulted in increased levels of Drosophila phospho-ERK, as judged by western blot (Figure 7c ).
Discussion
Members of the PI3K/AKT pathway are frequently involved in tumorigenesis and are considered attractive targets for cancer therapy. However, the diverse functions of many of these proteins are still not fully understood. In this study we show that alternative splicing of the PI3K encoding gene, PIK3CD, produces a previously unknown protein, p37d. The p37d protein is expressed at high levels in human tumors, interacts with the regulatory p85 subunit and the small RAS GTPase, and possesses growth-promoting properties in cultured cells and in Drosophila.
p37d protein and mRNA were expressed at high levels in human tumors and were particularly high in some ovarian tumors. The ovarian tumors were of various stages, and this could be a reason for the low, medium or high levels of p37d in different samples (Figure 2b ). To address if this is stage dependent more samples are needed, as this could not be interpreted from our small data set. Full-length p110d was undetectable in all these tumors, suggesting that p37d is a specific product of PIK3CD that can be produced independently of the full-length protein. Interestingly, in the colon, p37d-mRNA levels were higher in stage II compared with stage III and IV tumors, and the mRNA levels were higher in histologically normal mucosa adjacent to tumors compared with the colon mucosa from healthy donors. In colorectal tumors we did find a correlation of p37d-mRNA levels and p110d-mRNA levels (Supplementary Figure 3) , indicating that the same transcription factors are involved, however, this correlation was not seen on the protein level in normal tissues (Figure 1d ). PIK3CD is mainly expressed in inflammatory cells, thus high degree of inflammation in the tumors and surrounding tissues could be an explanation for increased expression of p110d and p37d mRNA, however, we could not find evidence of this after examining the level of the leukocyte specific mRNA CD45 in our samples (Supplementary Figure 2) . Previous studies have identified many genetic alterations in histologically normal mucosa adjacent to colorectal tumors (Chen et al., 2004; Polley et al., 2006) , and these alterations can be more important for prognosis than genetic alterations in the tumor itself (Odin et al., 2003; Wettergren et al., 2008) . The results suggest that increased expression of p37d may be an early event in the colon tumorigenesis.
It was recently shown that catalytically inactive forms of p110b are important in cell transformation and growth (Ciraolo et al., 2008; Jia et al., 2008) . Here we found that p37d, a catalytically inactive isoform of p110d, increases cell proliferation and invasion. Using HEK-293 cells that stably express p37d or p110d, we detected an increased proliferation rate in p37d-expressing cells that was not seen upon p110d expression, suggesting a unique proliferative role for p37d (Figure 4c) . A high level of p37d correlated with high The p110d isoform p37d is overexpressed in tumors S Fransson et al RAS levels and phosphorylated ERK1/2 in primary cells (Figure 5a ), a correlation that was not seen for p110d. Although it has a truncated RAS-binding domain, p37d appears to have a stabilizing effect on total RAS (Figures 5a and b) , possibly explaining a proliferative effect of overexpressed p37d. p37d overexpressing cells responded more quickly than control cells to serum stimulation by phosphorylation of both AKT S473 and ERK (Figure 6a ), and had a higher basal level of pAKT T308 (Figure 6b ), this could also result in higher proliferation rate of these cells. The growth advantage compared with control cells did not disappear after inhibition of neither the PI3K/AKT pathway nor the MAPK/ERK pathway (Figure 6c ). Possibly it is the interaction with the PI3K regulatory subunit, p85, that is, important in this context. p85 was recently shown to have tumor suppressive functions in malignant cells (Taniguchi et al., 2010) . The p85-binding domain of p37d is intact, and we show that p37d binds to p85 and that they aggregate in cytoplasmic foci. This effect was enhanced after IGF-1 -stimulation, indicating that these could be IRS1-p85 complexes previously reported to form after IGF-1 stimulation (Luo et al., 2005) . Further studies are needed, as we do see these aggregates in starved cells. This situation differs from co-expression of p85 and p110d, where p110d co-localize with p85 evenly distributed in the cytoplasm (Figure 3f ). p110d have a strong p85-binding capacity, and high abundance of p110d seems to prevent p85 from forming aggregates, p37d lack this capacity. Overexpression of p37d alone does not form aggregates (Figure 3e ), indicating that it is p85 that drives this process. Unlike p110d that stabilize p85 and protects it from proteasomal degradation, p37d has no such ability (Figures 3a and b) . In contrast, we consistently noted that the expression of p37d resulted in reduced levels of p85. Since this reduction in p85 levels could be alleviated upon proteasome inhibition, it is possible that p37d promotes protein degradation of p85.
To test this hypothesis we performed proliferation tests on HEK-293 cells transfected with p85a-siRNA ( Figure 4c ). This showed nearly identical effect as overexpression of p37d, thus increased proliferation. We also detected increased basal levels of pAKT T308 in the p85a-siRNA treated cells, similar to what we saw in p37d-expressing cells (Supplementary Figure 4 and Figure 6b ). The p85a-siRNA treated cells showed slightly elevated levels of p50a and p55a (Supplementary Figure 4 ). We believe it is unlikely that these smaller isoforms of p85a are involved in the ability of p37d to increase cell proliferation. First, p50a and p55a do not have the ability to positively regulate PTEN (Chagpar et al., 2010) and second, their levels were not increased in cells overexpressing p37d (not shown). Thus, overall our results suggest that p37d increases cell proliferation both by stabilizing RAS and by reducing levels of p85. The p37d-specific proliferative functions that were observed in human and mouse cells (Figure 4 ) could also be seen in vivo in the developing fly. Ubiquitous expression of p37d in flies resulted in increased fly size and weight, which was at least partly because of more cells in these flies, as the DNA content was also significantly higher, and the wing cell density was equal (Figure 7b ). We got a slightly larger difference in the DNA-content (12%) compared with the weight-difference (7%), and this could be explained by errors in the method, but also the fact that the weight of the fly is directly dependent on the size of the larvae, if the proliferation rate is too high, each cell just becomes smaller. As we have just investigated the cell size in the wing, it is still possible that other cells are slightly smaller in the p37d-expressing flies because of increased proliferation. The increase in fly size and weight also correlated with increased Drosophila pERK levels (Figure 7c) , however, other Drosophila proteins like p60 (corresponds to human p85) and AKT could also be affected.
We propose a mechanism of action of p37d where both the PI3K-AKT pathway and the RAS pathway are affected by p37d overexpression (Figure 8 ). In the PI3K AKT pathway we propose that p37d acts by degrading or sequestering free p85 and as a consequence the positive The p110d isoform p37d is overexpressed in tumors S Fransson et al regulation of PTEN is abolished, leading to increased AKT phosphorylation. We also propose that p37d stabilizes total RAS levels, leading to increased ERK phosphorylation, and possibly increased PI3K activity.
In conclusion, several lines of evidence argue that p37d has growth-promoting properties. First, elevated levels of p37d are detected in tumors. Second, p37d overexpression in human and mouse cell lines increases proliferation and invasion. Third, p37d expression in Drosophila results in increased body size and a higher DNA content. Thus, p37d could be a useful future target for cancer diagnosis and treatment.
Materials and methods
Plasmids
PIK3CD_v2 (p37d-mRNA) (GenBank: JN190435) and PIK3CD (p110d-mRNA) were amplified from human cDNA, PIK3R1 from the MGC image clone 30528412, and cloned into pDsRed-Monomer-N1 and pAc-GFP1-N2 vectors (Clontech, Mountain View, CA, USA), creating constructs both with and without dsRed/GFP1-fusion tags. PIK3CD_v2 were also cloned into the pUASTattB vector, kindly provided by Bischof et al. (2007) . All constructs were verified by BigDye Cycle Sequencing (Applied Biosystems).
Transfection, imaging and cell proliferation HEK-293 cells were transfected using Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA). MEFs, immortalized with the 3T3 method was transfected using FuGENE HD Transfection reagent (Roche Applied Science, Penzberg, Germany). For selection of stable clones, G418 (SigmaAldrich, St Louis, MO, USA) was used at 5 mg/ml. Positive clones were identified by western blot or real time-PCR. For proteasome inhibiton, 5 mM proteasome inhibitor (sc-3127, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to the medium at time of transfection, cells were incubated overnight before protein extraction. The siRNA treatment was performed using Lipofetamine RNAiMAX (Invitrogen) with 3.3 nM PIK3CD siRNA (sc-39131) or scrambled control siRNA (sc-37007), Santa Cruz Biotechnology. In the p85a-siRNA treatment we used 0.5-5 nM PIK3R1 siRNA (s10536) or negative control (s10536), both siRNAs from Ambion (Austin, TX, USA). PI3K and MAPK inhibition were performed with 30 mM LY294002 and 1 mM AZD6244, respectively (Selleck chemicals, Houston, TX, USA). Serum stimulations were performed on HEK-293 cells serum starved over night, 10% fetal bovine serum added for various times, followed by immediate protein extraction. Cellular localizations of fluorescently tagged proteins were recorded by laserscanning confocal microscopy using a Zeiss LSM 510 META system, on serum-starved cells or after IGF-1 stimulation (100 ng/ml, Sigma-Aldrich) for 20 min. For proliferation experiments cells were seeded in quadruplicates in 96-well plates. Viability was monitored during 4 days post transfection using CellTiter96 Aqueous One Solution (Promega, Madison, WI, USA), and for cell invasive test BD BioCoat Matrigel Invasion Chambers (BD Bioscience, Franklin Lakes, NJ, USA) were used. All experiments were repeated four times.
Real time-PCR expression analysis
Total RNA was extracted from primary tumors using Totally RNA (Ambion) and DNase-treated using DNAfree (Ambion). For normal tissue controls RNA from First Choice Human Total RNA (Ambion) and Total RNA (Clontech) were used, these are pooled total RNA from a minimum of three healthy donors. cDNA was synthesized from 1 mg of total RNA. Reverse transcription was performed using SuperScript II Reverse Transcriptase (Invitrogen) and random hexamer primers (Promega). Primers and probes were designed and produced using TaqMan Assays-by-Design (Applied Biosystems; Supplementary Figure 6 ). For CD45 detection Assay hs00365634_g1 (Applied Biosystems) was used. Real time-PCR was performed using ABI PRISM 7900HT (Applied Biosystems). For standard curves and calculation of absolute amounts of PIK3CD-mRNA, cDNA vectors with full length p37d-mRNA and p110d-mRNA were mixed at nine different concentrations ranging from 0.02-124 fg/reaction in the real time-PCR reaction. All measurements were performed in triplicates and the mean CT-value was used.
Protein isolation, SDS-PAGE, western blot and antibodies Protein was extracted using RIPA lysis buffer supplemented with HALT Phosphatase and Protease inhibitor cocktail (Thermo Scientific, Pierce, Rockford, IL, USA). Normal human tissue controls were purchased as Protein Medleys (Clontech) except the normal colon protein that was obtained from BioChain Institute Inc. (Hayward, CA, USA). Relative protein expression was calculated by band density measurements normalized to gapdh using ImageJ 1.42q software (NIH, Bethesda, MO, USA). Immunoprecipitations were performed with mMacs columns and protein A-beads (Miltenyi Biotec Gmbh., Bergisch Gladbach, Germany). Mouse polyclonal antibody to N-terminal p110d and p37d were purchased from BD Bioscience (#611015), C-terminal p37d-specific polyclonal antibodies were produced in rabbit using a mix of the p37d-specific C-terminal peptides N-CHLPGVHQGRAAGAD-C and N-CGGAAGRLHAAGERQ-C (Agrisera, Va¨nna¨s, Sweden), specificity is shown in Supplementary Figure 7 . Rabbit polyclonal antibodies to p85 (sc-423), gapdh (sc-825778), C-terminal p110d (sc-7176) and H-RAS (sc-520), AKT (sc-8312), pAKT S473 (sc-7985-R) and pAKT T308 (sc-16646-R) were from Santa Cruz Biotechnology, RAS (80-1735) from Assay Designs Inc. (Ann Arbor, MI, USA), pERK1/2 (9101) and ERK1/2 (9102) from Cell Signaling Technology (Danvers, MA, USA) and p85a (06-496) from Millipore. The p110d isoform p37d is overexpressed in tumors S Fransson et al
